OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 7 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).
Antibody Mediated Rejection in Organ Transplantation
Submission Deadline: September 30, 2019 (Open)
Ignatius Tang, MD, PharmD, FASN, FAST, FACP
Associate Professor of Clinical Medicine, Medical Director, Kidney, Pancreas and Islet Transplant Programs, Director, Live Donor Kidney Transplant Program, Section of Nephrology, Department of Medicine, University of Illinois Medical Center at Chicago, 820 South Wood Street, M/C 793, Chicago, IL 60612, USA
Website | E-Mail
Research Interests: Antibody-mediated syndromes (antibody-mediated rejection, accommodation, transplant glomerulopathy); BK viral kinetics and immunosuppression; outcomes of obese kidney transplant recepients
About This Topic
Organ transplantation is a curative therapy for hundreds of thousands of patients with end-stage organ failure. However, long-term outcomes have not improved, and nearly half of transplant recipients will lose their allografts by 10 years after transplant. One of the major challenges facing clinical transplantation is antibody-mediated rejection (AMR) caused by anti-donor HLA antibodies.
Antibody mediated rejection (AMR) poses a significant and continued challenge for long term graft survival in organ transplantation. However, in the recent years, there has emerged an increased understanding of the varied manifestations of the antibody mediated processes in organ transplantation.
This special issue aims to describe the clinical and histological manifestations of AMR, and discusses the immunopathological mechanisms contributing to antibody-mediated allograft injury as well as current and emerging therapies.
Rene J. Duquesnoy, Marilyn Marrari
Received: December 13, 2019; Published: February 11, 2020; doi:10.21926/obm.transplant.2001099
Maurizio Salvadori, Aris Tsalouchos
Received: October 13, 2019; Published: December 02, 2019; doi:10.21926/obm.transplant.1904093
Elizabeth F. Wallin, Michelle A. Linterman, Kathryn J. Wood
Received: June 02, 2019; Published: August 19, 2019; doi:10.21926/obm.transplant.1903079